We are live on ! Find out more
GBIO

Generation Bio
GBIO

Delisted

GBIO was delisted on the 6th of February, 2026.

Back to rankings

91 hedge funds and large institutions have $364M invested in Generation Bio in 2022 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 35 increasing their positions, 24 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

11,000% more call options, than puts

Call options by funds: $111K | Put options by funds: $1K

55% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 11

46% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 24

3% more funds holding

Funds holding: 88 → 91 (+3)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.21% less ownership

Funds ownership: 9.91% → 9.7% (-0.21%)

13% less capital invested

Capital invested by funds: $416M → $364M (-$52.3M)

Holders
91
Holders Change
+3
Holders Change %
+3.41%
% of All Funds
1.53%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
17
Increased
35
Reduced
24
Closed
11
Calls
$111K
Puts
$1K
Net Calls
+$110K
Net Calls Change
+$109K

Top Buyers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
+$14.4M
2
BlackRock
BlackRock
New York
+$2.18M
3
Renaissance Technologies
Renaissance Technologies
New York
+$1.4M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$1.1M
5
N
Nuveen
North Carolina
+$914K

Top Sellers

Rank Fund Capital Flow
1
CC
Casdin Capital
New York
-$9.72M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$8.75M
3
BI
BVF Inc
California
-$8.15M
4
FCM
Farallon Capital Management
California
-$3.94M
5
Two Sigma Investments
Two Sigma Investments
New York
-$673K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citigroup
76
Citigroup
New York
$33K -$96.9K -1,483 -74%
QT
77
Quantbot Technologies
New York
$30K -$22.3K -341 -43%
AIP
78
Ameritas Investment Partners
Nebraska
$21K – – –
MCM
79
Manchester Capital Management
Vermont
$20K +$13.1K +200 +200%
MLICM
80
Metropolitan Life Insurance Company (MetLife)
New York
$20K – – –
Wells Fargo
81
Wells Fargo
California
$18K -$22.5K -344 -56%
Barclays
82
Barclays
United Kingdom
$17K -$31.1K -476 -65%
Canada Life
83
Canada Life
Manitoba, Canada
$16K +$1.37K +21 +9%
CC
84
Cannell Capital
Wyoming
$11K +$11.4K +175 New
CLOS
85
Compagnie Lombard Odier SCmA
Switzerland
$7K – – –
Macquarie Group
86
Macquarie Group
Australia
$3K – – –
US Bancorp
87
US Bancorp
Minnesota
$2K – – –
S
88
SignatureFD
Georgia
$2K +$1.76K +27 +300%
LC
89
Lindbrook Capital
California
$2K +$1.83K +28 New
Daiwa Securities Group
90
Daiwa Securities Group
Japan
$1K – – –
CA
91
Clearstead Advisors
Ohio
$1K +$654 +10 New
TWA
92
TCI Wealth Advisors
Arizona
$1K +$654 +10 New
CC
93
Casdin Capital
New York
– -$9.72M -132,428 Closed
OQS
94
Occudo Quantitative Strategies
Florida
– -$280K -3,812 Closed
Squarepoint
95
Squarepoint
New York
– -$277K -3,776 Closed
SSA
96
Schonfeld Strategic Advisors
New York
– -$224K -3,040 Closed
Thrivent Financial for Lutherans
97
Thrivent Financial for Lutherans
Minnesota
– -$146K -1,984 Closed
ProShare Advisors
98
ProShare Advisors
Maryland
– -$103K -1,412 Closed
Rafferty Asset Management
99
Rafferty Asset Management
New York
– -$82K -1,114 Closed
PCM
100
Prelude Capital Management
New York
– -$74K -1,010 Closed
1 2 3
4
5

GBIO Hedge Fund Activity: Q2 2022 in Review

91 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Generation Bio (GBIO) for Q2 2022, worth a combined $364M — down 13% from $416M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new GBIO positions and 11 closed out — a net gain of 6 holders — while 35 added to existing stakes and 24 trimmed.

The largest buyer was PFM Health Sciences, adding an estimated $14.4M. The largest seller was Casdin Capital, exiting entirely with an estimated $9.72M sold.

  • 91 institutional investors held Generation Bio (GBIO) as of Q2 2022, up from 88 in Q1 2022.
  • Funds reported $364M of Generation Bio stock for Q2 2022, down 13% quarter-over-quarter.
  • 17 funds opened new Generation Bio positions in Q2 2022 and 11 closed out, a net change of +6 holders.
  • The largest Generation Bio buyer in Q2 2022 was PFM Health Sciences, an estimated $14.4M added.
  • The largest Generation Bio seller in Q2 2022 was Casdin Capital, an estimated $9.72M sold.

Based on aggregated 13F filings for Q2 2022.